Alnylam Pharmaceuticals is surging nearly 16% in pre-market trading. The rally comes after AstraZeneca and Ionis jointly announced that their ATTR-CM (transthyretin amyloid cardiomyopathy) drug, Wainua (eplontersen), failed to meet its primary efficacy endpoint in a pivotal Phase III trial. This development signals a significant easing of competitive pressure for Alnylam in the field.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.